Impact of ovarian function suppression on prognosis in premenopausal patients with HR+/HER2 + early-stage breast cancer: a multi-center retrospective study
Our study confirms that premenopausal patients with HR+/HER2 + early-stage breast cancer could benefit from additional OFS after trastuzumab treatment.
Authors
- Debo Chen (ORCID: https://orcid.org/0000-0003-3524-063X)
- Weibin Lian
- Chengye Hong
- Liangqiang Li (ORCID: https://orcid.org/0000-0002-4307-4048)
Institutions
- Fujian Medical University (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1186/s12885-025-14774-w
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Jiao Tong University
- Quanzhou City Science and Technology Program